G Agnelli, P Prandoni, C Becattini, M … - Annals of internal medicine, 2003 - Am Coll Physicians Background: The optimal duration of oral anticoagulant treat- ment after a first
episode of pulmonary embolism remains uncer- tain. Objective: To evaluate the
long-term clinical benefit of extend- ing a 3-month course of oral ... Cited by 116 - Related articles - BL Direct - All 10 versions
- ►ahajournals.org L Pinede, J Ninet, P Duhaut, S Chabaud, S … - Circulation, 2001 - Am Heart Assoc Methods and Results—We performed an open-label, randomized trial comparing a
short oral anticoagulant course (3 months for proximal deep vein thrombosis
[P-DVT] and/or pulmonary embolism [PE]; 6 weeks for isolated calf DVT ... Cited by 187 - Related articles - BL Direct - All 9 versions
- ►diegori.it [PDF] G Agnelli, P Prandoni, MG Santamaria, P … - New England Journal of Medicine, 2001 - content.nejm.org Results The primary intention-to-treat analysis showed that of 134 patients
assigned to continued oral anticoagulant therapy, 21 had a recurrence of venous
thromboembolism (15.7 percent; average follow-up, 37.8 months), as compared ... Cited by 300 - Related articles - BL Direct - All 10 versions
S Murin, PS Romano, RH White - Thrombosis and haemostasis, 2002 - cat.inist.fr Venous thrombosis and pulmonary embolism are commonly viewed as different
manifestations of a single disease process, venous thromboembolism. Recent
evidence suggests that there may be important differences between patients ... Cited by 91 - Related articles - BL Direct - All 3 versions
- ►velcec.com [PDF] C Kearon, JS Ginsberg, MJ Kovacs, DR … - New England Journal of Medicine, 2003 - content.nejm.org Clive Kearon, MB, Ph.D., Jeffrey S. Ginsberg, MD, Michael J. Kovacs, MD, David
R. Anderson, MD, Philip Wells, MD, Jim A. Julian, M.Math., Betsy MacKinnon,
M.Sc., Jeffrey I. Weitz, MD, Mark A. Crowther, MD, Sean Dolan, MD, ... Cited by 320 - Related articles - BL Direct - All 20 versions
MN Levine, J Hirsh, M Gent, AG Turpie, J … - Thrombosis and haemostasis, 1995 - ncbi.nlm.nih.gov 1: Thromb Haemost. 1995 Aug;74(2):606-11. Optimal duration of oral
anticoagulant therapy: a randomized trial comparing four weeks ... Cited by 249 - Related articles - BL Direct - All 3 versions
C Kearon, JS Ginsberg, DR Anderson, MJ … - Journal of Thrombosis and Haemostasis, 2004 - interscience.wiley.com Summary. Background: The risk of recurrence is lower after treatment of an
episode of venous thromboembolism associated with a transient risk factor, such
as recent surgery, than after an episode associated with a permanent, or ... Cited by 39 - Related articles - BL Direct - All 4 versions
- ►annals.org [PDF] JD Douketis, CS Gu, S Schulman, A … - Annals of Internal Medicine, 2007 - Am Coll Physicians Objective: To provide reliable and precise estimates of the annual risk for
fatal PE and the case-fatality rate of disease recurrence and to assess these
outcomes according to the initial presentation of VTE (deep venous ... Cited by 35 - Related articles - BL Direct - All 5 versions
S Eichinger, A Weltermann, E Minar, M Stain, … - Archives of Internal Medicine, 2004 - Am Med Assoc Results Recurrent VTE was seen among 28 (17.3%) of 162 patients with symptomatic
PE and among 26 (9.5%) of 274 patients with DVT without symptoms of PE. Compared
with patients with DVT, the relative risk of recurrent VTE among patients ... Cited by 62 - Related articles - BL Direct - All 6 versions
- ►annals.org [PDF] LA Linkins, PT Choi, JD Douketis - Annals of internal medicine, 2003 - Am Coll Physicians Background: Clinicians should consider the clinical impact of
anticoagulant-related bleeding when deciding on the duration of anticoagulant
therapy in patients with venous thromboembolism. Purpose: To provide ... Cited by 208 - Related articles - BL Direct - All 5 versions
